Tatva Chintan Pharma Chem Ltd (TATVA) — Announcement | 8 September 2026 (2 announcements)

Tatva Chintan Pharma Chem announced a credit rating upgrade from CRISIL BBB+/Stable to A-/Stable for long-term facilities and from A2 to A2+ for short-term facilities, reflecting improved creditworthiness and outlook stability. The revision covers all bank loan facilities totaling Rs.245 crores across multiple lenders, with the rating letter valid until March 31, 2027.

Tatva Chintan Pharma Chem announced its schedule for upcoming analyst and investor meetings, including a one-on-one virtual session with HSBC Securities and Capital on September 15, 2026, as part of its ongoing investor engagement under SEBI's LODR Regulation 30. The company emphasized that all discussions will rely solely on publicly available information and will not involve any unpublished price-sensitive information. This structured outreach aims to enhance transparency and provide investors with direct access to management while adhering to regulatory disclosure norms.